Fibrosis Models
Advanced fibrosis models that replicate key disease processes to accelerate antifibrotic drug development
At NEPHRIX Biosolutions, we have built a strong reputation in renal fibrosis research and have now extended our expertise to encompass other critical areas of fibrotic disease, including cardiac, liver and pulmonary fibrosis. Using state-of-the-art preclinical models and advanced histological analysis, we reproduce the key mechanisms of fibrotic progression and evaluate therapeutic efficacy with high translational relevance.
In addition to our validated in vitro fibrosis assays, we developped animal fibrosis models that accelerate the development of anti-fibrotic therapies. Combined with our full suite of analytical services, from biomarker quantification to comprehensive tissue characterization,
You have a specific project, contact us and we will be happy to propose you a study plan fitting your specific needs.
- Carbon tetrachloride (CCl4) induction
- High-fat & cholesterol diet (HFCD) induction, with hyperlipidemia
Pulmonary fibrosis is a progressive scarring of lung tissue resulting from chronic injury or disease, which can ultimately lead to impaired respiratory function and respiratory failure. We offer preclinical pulmonary fibrosis models, including:
- Bleomycin (BLM)-induced pulmonary fibrosis
- Chronic pulmonary bacterial infection
Cardiac fibrosis is a hallmark of many cardiovascular diseases, leading to myocardial stiffening, impaired function and heart failure. We developped preclinical cardiac fibrosis models :
- DOCA-Salt + Ux rat model (Reactive fibrosis)
- Isoprenaline-induced MI (Reparative fibrosis)
Our kidney fibrosis models ensure high translational value for preclinical drug assessment:
- UUO (Unilateral Ureteral Obstruction)
- Ischemia reperfusion
- Adenine diet
